Showing results (11-20 of 44) with videos related to
Sort By:
Pageof 5
The Journal of Molecular Diagnostics : JMD|March 20, 2012
KRAS and BRAF mutation analysis in routine molecular diagnostics: comparison of three testing methods on formalin-fixed, paraffin-embedded tumor-derived DNADaniëlle A M Heideman, Irene Lurkin, Marije Doeleman, et al.Clinical Immunology (Orlando, Fla.)|May 19, 2016
Differential effects of inhibitors of the PI3K/mTOR pathway on the expansion and functionality of regulatory T cellsCharlotte M Huijts, Saskia J Santegoets, Maria Quiles Del Rey, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 24, 2015
PET/CT-derived whole-body and bone marrow dosimetry of 89Zr-cetuximabNikolaos E Makris, Ronald Boellaard, Arthur van Lingen, et al.Therapeutic Drug Monitoring|October 2, 2014
Therapeutic drug monitoring to individualize the dosing of pazopanib: a pharmacokinetic feasibility studyDjoeke de Wit, Nielka P van Erp, Jan den Hartigh, et al.Immunology|June 18, 2016
Generation and characterization of CD1d-specific single-domain antibodies with distinct functional featuresRoeland Lameris, Renée C G de Bruin, Paul M P van Bergen En Henegouwen, et al.BMC Cancer|December 2, 2011
Phase I-II study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell cancerCharlotte M Huijts, Saskia J Santegoets, Alfons J van den Eertwegh, et al.Cancer Immunology, Immunotherapy : CII|January 18, 2019
The effect of everolimus and low-dose cyclophosphamide on immune cell subsets in patients with metastatic renal cell carcinoma: results from a phase I clinical trialCharlotte M Huijts, Sinéad M Lougheed, Zuhir Bodalal, et al.Molecular Cancer Therapeutics|May 27, 2010
Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft studyHans J Hammers, Henk M Verheul, Brenda Salumbides, et al.Cancer Research|May 13, 2010
MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activityElisa Giovannetti, Niccola Funel, Godefridus J Peters, et al.Blood|August 12, 2011
Blood platelets contain tumor-derived RNA biomarkersR Jonas A Nilsson, Leonora Balaj, Esther Hulleman, et al.Pageof 5